Journal articleClin Cancer Res2025
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.
- Journal
- Clin Cancer Res
- Published
- 1 September 2025
- Citations
- 19
- Type
- Article
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 8
- Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
- Core A: Administrative Core P50CA272213↗
- The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer R01CA177670↗
- Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy R01CA244938↗
- Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity R01CA248917↗
- Re-wiring PDAC Tumor Immunity Through Dendritic Cells R01CA262506↗
- Stomal Senescence Regulator of Tumor Immunity and Progression R01CA286615↗
- The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity U01CA284086↗